First-in-human Phase 1 clinical trial of Nelmastobart,
the first BTN1A1-inhibiting antibody
for advanced solid tumors, has been completed
| Clinical Development Status | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approval |
|---|
| CRC |
Phase 1b/2 Clinical Trial (Biomarker-Driven)
|
||||
|
Investigator-Initiated Phase 1b/2 Clinical Trial
|
|||||
| NSCLC |
Phase 2 Clinical Trial (Biomarker-Driven)
|
||||
